Skip to content

ADA Standards of Care 2026: diabetes

International American Diabetes Association Current

Standards of Care in Diabetes—2026

American Diabetes Association Professional Practice Committee. Diabetes Care. 2026;49(Suppl 1):S1–S377
Summary checked against the source: 2026-11

Read or download the original

ADA updates its Standards every January. This page covers diagnosis, glycaemic goals, hypoglycaemia, drug treatment, cardiovascular and kidney protection, complications and hospital care. Citations give the evidence grade and the supplement page (S…).

At a glance

  1. Diagnose with A1C ≥6.5%, fasting glucose ≥126 mg/dL, 2-h OGTT ≥200 mg/dL, or random ≥200 mg/dL with symptoms. Confirm unless hyperglycaemia is unequivocal. [B · S27]
  2. A1C goal <7% for most adults; time in range >70% on CGM. [A · S135]
  3. Organ protection comes before glucose: an SGLT2i or GLP-1 RA with proven benefit for ASCVD, heart failure or CKD, whatever the A1C. [A · S190]
  4. GLP-1-based therapy is preferred to insulin for starting or adding treatment unless glucose is very high. [A · S192]
  5. Start insulin with symptoms of hyperglycaemia, A1C >10% or glucose ≥300 mg/dL. [E · S192]
  6. BP goal <130/80; ACEi or ARB first if there's albuminuria. [A · S218, S221]
  7. Statin for everyone aged 40–75; high-intensity if at higher risk; LDL <55 mg/dL with ASCVD. [A · S223]
  8. CKD with albuminuria: RAS inhibitor + SGLT2i + finerenone (+ GLP-1 RA). [A · S252, S255]

Diagnosis

Test Diabetes Prediabetes
A1C ≥6.5% (48 mmol/mol) 5.7–6.4% (39–47 mmol/mol)
Fasting plasma glucose (≥8 h fast) ≥126 mg/dL (7.0 mmol/L) 100–125 mg/dL (5.6–6.9): IFG
2-h glucose, 75-g OGTT ≥200 mg/dL (11.1 mmol/L) 140–199 mg/dL (7.8–11.0): IGT
Random glucose ≥200 mg/dL with classic symptoms or crisis

Without unequivocal hyperglycaemia, confirm with two abnormal results from the same sample or two separate samples. Adapted from ADA 2026 Tables 2.1 and 2.2 [S28]

  • Use glucose, not A1C, when the A1C–glucose link is altered: haemoglobin variants, pregnancy, G6PD deficiency, HIV, haemolysis, recent transfusion. [B · S29]
  • Screen adults with overweight or obesity plus a risk factor at any age, and everyone from age 35. Repeat at least every 3 years. [B · S35]
  • Second-generation antipsychotics: screen at baseline, at 12–16 weeks, then yearly. [B · S35]
  • After acute pancreatitis, screen at 3–6 months and yearly. Post-transplant diabetes: OGTT is the preferred test. [S39–S40]
  • Diabetes in the first 6 months of life: genetic testing for neonatal diabetes. Autosomal-dominant family history, atypical features: test for MODY. [A · S41]

Gestational diabetes

  • Before 15 weeks: test those with risk factors for undiagnosed diabetes. At 24–28 weeks: screen everyone not already diagnosed. [S42]
  • One-step 75-g OGTT: GDM if any value is met: fasting ≥92 mg/dL, 1 h ≥180, 2 h ≥153. [Table 2.8 · S43]
  • After GDM: OGTT at 4–12 weeks postpartum, then lifelong screening every 1–3 years. [B · S42]

Glycaemic goals

Measure Goal for many non-pregnant adults
A1C <7% (53 mmol/mol)
A1C, healthy, low hypoglycaemia risk <6.5% may be appropriate
A1C, frail or limited life expectancy Less stringent
Time in range (70–180 mg/dL) >70%
Time below 70 mg/dL <4% (<1% in older adults)
Time below 54 mg/dL <1%

Adapted from ADA 2026 recommendations 6.3–6.5 [S135]

Monitoring [S132]

  • Check glycaemic status at least twice a year, and every 3 months if not at goal or treatment has changed. [E · S132]
  • Deintensify insulin, sulfonylureas or meglitinides in people at high risk of hypoglycaemia. [B · S135]

Hypoglycaemia

Level Definition
Level 1 Glucose <70 mg/dL (3.9 mmol/L) and ≥54 mg/dL
Level 2 Glucose <54 mg/dL (3.0 mmol/L): neuroglycopenic symptoms start; act immediately
Level 3 Severe event needing another person's help, whatever the glucose

Adapted from ADA 2026 Table 6.4 [S139]

Treatment [S138]

  • Conscious, glucose <70 mg/dL: glucose is preferred (15–20 g). Avoid high-fat or high-protein foods first. Recheck at 15 minutes and repeat if still low. [B · S138]
  • Prescribe glucagon for everyone on insulin or at high risk, and teach family or carers to use it. [A · S138]
  • CGM for people at high risk of hypoglycaemia. [A · S138]
  • Screen for impaired hypoglycaemia awareness at least yearly. [A · S138]

Treating type 2 diabetes

flowchart TD
    L["Healthy lifestyle · DSMES · social determinants of health<br/>Reassess and modify every 3–6 months"] --> CV
    L --> WG
    subgraph CV ["Goal: cardiovascular and kidney risk reduction (irrespective of A1C)"]
        A["With ASCVD or indicators of high CVD risk"] --> A1["GLP-1 RA with proven CVD benefit<br/>and/or SGLT2i with proven CVD benefit"]
        A1 --> A2["If glycaemia above goal:<br/>on GLP-1 RA, add SGLT2i or vice versa;<br/>pioglitazone"]
        H["With heart failure"] --> H1["SGLT2i with proven HF benefit<br/>(HFrEF or HFpEF)"]
        H1 --> H2["Symptomatic HFpEF with obesity:<br/>tirzepatide or GLP-1 RA with proven benefit"]
        K["With CKD<br/>eGFR &lt;60 or UACR ≥30 mg/g"] --> K1["On maximally tolerated ACEi/ARB:<br/>SGLT2i with proven CKD benefit (start if eGFR ≥20)<br/>OR GLP-1 RA with proven CKD benefit"]
        K1 --> K2["If glycaemia above goal:<br/>on SGLT2i, add GLP-1 RA or vice versa"]
    end
    subgraph WG ["Goal: weight and glycaemic goals"]
        W["Weight management"] --> W1["Very high: semaglutide, tirzepatide<br/>High: dulaglutide, liraglutide<br/>Intermediate: other GLP-1 RA, SGLT2i<br/>Neutral: metformin, DPP-4i"]
        G["Glycaemic goals"] --> G1["Metformin or other agent, including<br/>combination therapy. Avoid hypoglycaemia<br/>in high-risk people"]
        G1 --> G2["Very high: dulaglutide (high dose), semaglutide,<br/>tirzepatide, insulin, injectable combinations<br/>High: other GLP-1 RA, metformin, pioglitazone,<br/>SGLT2i, sulfonylurea<br/>Intermediate: DPP-4i"]
    end
    CV --> M["With MASLD or MASH: GLP-1 RA, tirzepatide,<br/>pioglitazone, or GLP-1 RA + pioglitazone"]
Adapted from ADA 2026 Figure 9.4 [S191]

Grade A [S190–S192]

  • Consider combination therapy from the start to reach goals sooner. [A · S190]
  • ASCVD or high risk: a GLP-1 RA and/or SGLT2i with proven CV benefit, irrespective of A1C. [A · S190]
  • Heart failure (HFrEF or HFpEF): an SGLT2i. [A · S190]
  • Obesity with symptomatic HFpEF: tirzepatide or a GLP-1 RA with proven HF benefit. [A · S190]
  • CKD (eGFR 20–60 and/or albuminuria): an SGLT2i or GLP-1 RA with proven benefit. [A · S190]
  • GLP-1-based therapy is preferred to insulin without severe hyperglycaemia. If insulin is used, combine it with a GLP-1 RA. [A · S192]
  • Keep other glucose-lowering drugs going when insulin starts. Don't delay intensification. [A · S192]

Other points

  • eGFR <30: a GLP-1 RA is preferred, with less hypoglycaemia. [C · S190]
  • MASH or high fibrosis risk: GLP-1 RA preferred; pioglitazone or tirzepatide can be considered. [B · S192]
  • Start insulin with symptoms, A1C >10% or glucose ≥300 mg/dL, whatever the background treatment. [E · S192]
  • Don't combine a DPP-4 inhibitor with a GLP-1 RA. [B · S192]
  • Low-cost options where cost is a barrier: metformin, sulfonylureas, pioglitazone, human insulin. [E · S202]
  • Teach people on SGLT2i about ketoacidosis and how to check ketones. [E · S205]

Type 1 diabetes

  • Multiple daily injections or a pump with basal and prandial insulin; analogues are preferred to human insulin. [A · S183]
  • Teach carbohydrate counting. Offer automated insulin delivery to everyone on insulin. [B · S183; A · S202]

Blood pressure

Grade A [S217–S222]

  • Goal <130/80 if safely attainable; encourage SBP <120 with high CV or kidney risk. [A · S218]
  • Start drugs at ≥130/80. At ≥150/90, start two drugs or a single-pill combination. [A · S221]
  • ACEi or ARB first line with albuminuria (strongly recommended for UACR ≥300 mg/g). [A/B · S221]
  • Never combine ACEi, ARB, ARNI or a direct renin inhibitor. [A · S221]
  • Not at goal on three drugs including a diuretic: add an MRA. [A · S222]
  • Avoid ACEi, ARB and MRA without reliable contraception. [A · S221]

Lipids and antiplatelets

Situation Statin Goal
Age 20–39 with ASCVD risk factors May be reasonable
Age 40–75, no ASCVD Moderate intensity
Age 40–75, higher risk (≥1 risk factor) High intensity LDL ↓ ≥50% and <70 mg/dL
ASCVD, any age High intensity LDL ↓ ≥50% and <55 mg/dL
Over 75, already on a statin Continue
Over 75, not on one Moderate intensity may be reasonable

Adapted from ADA 2026 recommendations 10.18–10.27 [S223]

  • Add ezetimibe (or a PCSK9 inhibitor) if LDL stays above goal. Statin intolerance: bempedoic acid. [A · S223]
  • Triglycerides ≥500 mg/dL: look for secondary causes and treat to prevent pancreatitis. [C · S227]
  • Adding a fibrate, niacin or omega-3 supplements to a statin gives no CV benefit. [A · S228]
  • Aspirin 75–162 mg for secondary prevention; clopidogrel if allergic. Primary prevention only after discussing bleeding risk. [A · S229]
  • No routine screening for coronary disease in people without symptoms. [A · S230]

Kidney disease

Grade A and B [S246–S257]

  • Check UACR and eGFR yearly: from diagnosis in type 2, and after 5 years in type 1. [B · S246]
  • BP <130/80; aim to cut albuminuria by ≥30% if UACR ≥300 mg/g. [A · S250; B · S249]
  • Continue RAS blockade if creatinine rises by ≤30% without volume depletion. [A · S251]
  • SGLT2i for type 2 diabetes with CKD; it can be continued below eGFR 20 until dialysis. [A · S252; C · S256]
  • GLP-1 RA with proven kidney benefit. [A · S252]
  • Finerenone for CKD with albuminuria if eGFR ≥25. [A · S255]
  • Protein 0.8 g/kg/day in CKD G3 or worse; 1.0–1.2 g/kg/day on dialysis. [A/B · S250]
  • Refer to a nephrologist if eGFR <30, or UACR or eGFR changes rapidly. [A · S257]

Not recommended

  • ACEi or ARB for primary prevention of CKD with normal BP, UACR and eGFR. [A · S251]

Eyes, nerves and feet

Type 1 Type 2 Then
Dilated eye exam 5 years after onset At diagnosis Yearly; every 1–2 years if no retinopathy and glucose at goal
Neuropathy screen 5 years after onset At diagnosis At least yearly
Comprehensive foot exam At least yearly; every visit if sensory loss or previous ulcer

Adapted from ADA 2026 recommendations 12.3–12.25 [S262–S268]

  • Retinopathy: refer for macular oedema, moderate or worse NPDR, or any PDR. Panretinal laser for high-risk PDR. Anti-VEGF first line for centre-involving macular oedema. Retinopathy is not a contraindication to aspirin. [A · S263]
  • Pregnancy: eye exam before pregnancy and in the first trimester. [B · S262]
  • Neuropathy exam: pinprick or temperature (small fibres), 128-Hz tuning fork vibration (large fibres) and the 10-g monofilament. [B · S265]
  • Neuropathic pain: gabapentinoids, SNRIs, tricyclics or sodium-channel blockers first line. [A · S266]
  • PAD screen with ankle–brachial index at age ≥65, or with microvascular disease or foot complications. [B · S231]

Hospital care and hyperglycaemic crises

Inpatients [S340–S347]

  • Start insulin for persistent glucose ≥180 mg/dL (twice in 24 h). [A · S340]
  • Goal 140–180 mg/dL for most ICU and ward patients. [A · S340]
  • IV insulin infusion in critical illness. On the ward: basal + prandial + correction insulin; basal + correction with poor intake. [A · S342]
  • Correction-only "sliding scale" insulin is discouraged. [A · S342]
  • Treat DKA and HHS with IV fluids, insulin and electrolytes, find the cause, and overlap basal insulin before stopping the infusion. [A · S347]
DKA HHS
Glucose ≥200 mg/dL (11.1 mmol/L) or known diabetes ≥600 mg/dL (33.3 mmol/L)
Ketones β-hydroxybutyrate ≥3.0 mmol/L or urine ketones 2+ β-hydroxybutyrate <3.0 mmol/L, urine ketones <2+
Acid–base pH <7.3 and/or bicarbonate <18 mmol/L pH ≥7.3 and bicarbonate ≥15 mmol/L
Osmolality Effective >300 mOsm/kg [2 × Na + glucose] or total >320 [2 × Na + glucose + urea]
Onset Hours to days; usually alert; Kussmaul breathing, abdominal pain Days to a week; altered consciousness common

One-third of hyperglycaemic emergencies are mixed DKA–HHS. Adapted from ADA 2026 Tables 16.1 and 16.2 [S349]

  • Basal insulin 2–4 h before stopping the IV infusion prevents rebound ketoacidosis. Mild DKA can be treated with subcutaneous rapid-acting insulin every 1–2 h. Bicarbonate is generally not recommended. [S349]
  • Risk factors for crises: type 1 diabetes, young age, previous crises, high A1C, insulin rationing, SGLT2 inhibitors, substance use, mental illness. [Table 6.8 · S144]

Clinical pearls

  • Diagnostic numbers: 6.5 / 126 / 200 / 200. Prediabetes: 5.7–6.4 / 100–125 / 140–199.
  • GDM (one-step): 92 / 180 / 153.
  • Hypoglycaemia levels: <70, <54, needs help.
  • SGLT2i: HF and CKD (continue below eGFR 20); risk of euglycaemic DKA.
  • Finerenone = non-steroidal MRA for diabetic kidney disease with albuminuria.
  • Eyes: type 1 at 5 years, type 2 at diagnosis.

Classes and levels of evidence

How ADA 2026 grades its recommendations. Adapted from ADA 2026 Table 1 (evidence-grading system) [S3]. Hover over any class or level cited on this page to see what it means.

Level Meaning
Grade A Clear evidence from well-conducted, generalisable, adequately powered RCTs (e.g. a multicentre trial, or a meta-analysis that incorporated quality ratings), or supportive evidence from such trials
Grade B Supportive evidence from well-conducted cohort studies or registries, a meta-analysis of cohort studies, or a well-conducted case-control study; or RCTs with a flaw that may limit validity
Grade C Supportive evidence from poorly controlled or uncontrolled studies (flawed RCTs, observational studies with high risk of bias, case series or reports), or conflicting evidence with the weight supporting the recommendation
Grade E Expert consensus or clinical experience

ADA grades only the quality of the evidence behind each recommendation, not its strength. Every numbered statement is a recommendation; the letter says how well it is supported. Some statements carry more than one letter, one for each part.